#China #Suzhou #Boehringer Ingelheim #MASH #Ribo

Ribo and Boehringer Ingelheim Make Significant Progress in siRNA Research for MASH

Suzhou Ribo Life Science Co., Ltd., in collaboration with Ribocure Pharmaceuticals AB, also known as Ribo, has announced a remarkable achievement in advancing their research on small interfering RNA (siRNA) therapies aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). This development marks the third critical milestone reached in their ongoing partnership with the pharmaceutical giant Boehringer Ingelheim, highlighting the commitment of both entities to combat liver diseases through innovative research.

MASH is a severe and progressive liver condition characterized by the accumulation of fat in the liver, which can lead to more serious health issues, including fibrosis, cirrhosis, liver failure, and even liver cancer. According to global statistics, over 200 million individuals are affected by this debilitating disorder. The rising prevalence of MASH underscores the urgent need for effective treatment solutions that can mitigate the disease's progression and promote liver health.

The collaboration between Ribo and Boehringer Ingelheim aims to develop and expand a diverse range of treatment options for patients suffering from MASH. Co-CEO and Global R&D President of Ribo, Li-Ming Gan, expressed pride in the progress made, stating, "This is an important step forward and highlights the strength and maturity of our siRNA discovery and liver-targeted delivery capabilities. Together, we are advancing a highly innovative program that aims to bring much-needed options to people suffering from MASH."

The project's foundation lies in the application of siRNA therapeutics, designed to silence specific genes implicated in disease progression by targeting their respective messenger RNAs (mRNAs). Ribo's unique liver-targeting delivery system enhances the selective uptake of these therapeutic agents by hepatocytes, ensuring that treatment can effectively reach areas of need — particularly those challenging to address with traditional small molecule drugs or antibodies.

This recent milestone not only underscores the productivity of the Ribo-Boehringer Ingelheim partnership but also reflects their shared ambition to find viable solutions for unmet medical needs in liver and cardiometabolic diseases. The achievement solidifies Ribo's standing as a strategic collaborator for global pharmaceutical companies, spotlighting the market potential of its siRNA platform.

Ribo remains committed to propelling this collaboration forward with promising prospects for ongoing success throughout 2026 and beyond. As they continue to push the boundaries of research and development in this vital area, both Ribo and Boehringer Ingelheim are poised to contribute significantly to the evolving landscape of liver disease treatment and recovery. By innovating therapy options, this partnership aims not only to address the immediate challenges associated with MASH but also to improve quality of life for millions affected by this chronic condition.

In summary, the collaborative efforts of Suzhou Ribo Life Science and Boehringer Ingelheim represent a beacon of hope for individuals combating metabolic dysfunction-associated steatohepatitis. Their work in advancing siRNA therapies marks a pivotal moment in the fight against liver diseases, paving the way for a healthier future for many.